Literature DB >> 7854984

Synthesis and biological evaluation of alpha-MSH analogues substituted with alanine.

U G Sahm1, G W Olivier, S K Branch, S H Moss, C W Pouton.   

Abstract

The influence of single amino acid replacements by alanine on the binding affinity and biological activity of alpha-MSH in B16 murine melanoma cells has been studied systematically. alpha-MSH analogues were synthesized by solid-phase peptide synthesis and their binding affinities to the melanocortin receptor expressed by B16 mouse melanoma cells were determined using a radioreceptor assay. Biological activity of the analogues was determined by measuring tyrosinase stimulation. Relative activity and affinity data were generally in agreement with earlier results using terminal deletion fragments of alpha-MSH, but the alanine scan revealed important new insights into the role of individual residues. The three terminal amino acids at either end were not necessary for binding or activity, with amino acids 4-9 forming a core sequence required for receptor binding and triggering of the biological response. It was observed that replacement of the glutamic acid residue in position 5 was possible without loss of affinity or activity, whereas replacement of Met4 resulted in a 100-fold loss of binding affinity and biological activity. Each residue within the conserved melanocortin sequence His-Phe-Arg-Trp was shown to be essential with Phe7, Arg8, and Trp9 being the most sensitive to replacement by alanine. Generally, there was a rank correlation between binding affinity and tyrosinase stimulation within the group of analogues studied. Tyrosinase activity was less affected by alanine substitution than binding affinity, which suggests that full receptor binding is not required for maximum biological response.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7854984     DOI: 10.1016/0196-9781(94)90157-0

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  13 in total

1.  Structure-activity relationships of peptides incorporating a bioactive reverse-turn heterocycle at the melanocortin receptors: identification of a 5800-fold mouse melanocortin-3 receptor (mMC3R) selective antagonist/partial agonist versus the mouse melanocortin-4 receptor (mMC4R).

Authors:  Anamika Singh; Marvin Dirain; Rachel Witek; James R Rocca; Arthur S Edison; Carrie Haskell-Luevano
Journal:  J Med Chem       Date:  2013-03-25       Impact factor: 7.446

2.  A fragment of the Escherichia coli ClpB heat-shock protein is a micromolar melanocortin 1 receptor agonist.

Authors:  Mark D Ericson; Sathya M Schnell; Katie T Freeman; Carrie Haskell-Luevano
Journal:  Bioorg Med Chem Lett       Date:  2015-09-21       Impact factor: 2.823

Review 3.  Bench-top to clinical therapies: A review of melanocortin ligands from 1954 to 2016.

Authors:  Mark D Ericson; Cody J Lensing; Katlyn A Fleming; Katherine N Schlasner; Skye R Doering; Carrie Haskell-Luevano
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2017-03-29       Impact factor: 5.187

4.  Discovery of Melanocortin Ligands via a Double Simultaneous Substitution Strategy Based on the Ac-His-dPhe-Arg-Trp-NH2 Template.

Authors:  Aleksandar Todorovic; Cody J Lensing; Jerry Ryan Holder; Joseph W Scott; Nicholas B Sorensen; Carrie Haskell-Luevano
Journal:  ACS Chem Neurosci       Date:  2018-06-11       Impact factor: 4.418

5.  Comparative Functional Alanine Positional Scanning of the α-Melanocyte Stimulating Hormone and NDP-Melanocyte Stimulating Hormone Demonstrates Differential Structure-Activity Relationships at the Mouse Melanocortin Receptors.

Authors:  Aleksandar Todorovic; Mark D Ericson; Ryan D Palusak; Nicholas B Sorensen; Michael S Wood; Zhimin Xiang; Carrie Haskell-Luevano
Journal:  ACS Chem Neurosci       Date:  2016-05-17       Impact factor: 4.418

6.  "Click"-cyclized (68)Ga-labeled peptides for molecular imaging and therapy: synthesis and preliminary in vitro and in vivo evaluation in a melanoma model system.

Authors:  Molly E Martin; M Sue O'Dorisio; Whitney M Leverich; Kyle C Kloepping; Susan A Walsh; Michael K Schultz
Journal:  Recent Results Cancer Res       Date:  2013

7.  Semi-rigid tripeptide agonists of melanocortin receptors.

Authors:  Andrew R Ruwe; Leonid Koikov; Zalfa Abdel-Malek; Carrie Haskell-Luevano; Marvin L Dirain; Federico Portillo; Zhimin Xiang; Matt Wortman; James J Knittel
Journal:  Bioorg Med Chem Lett       Date:  2009-07-09       Impact factor: 2.823

8.  Contribution of the transmembrane domain 6 of melanocortin-4 receptor to peptide [Pro5, DNal (2')8]-gamma-MSH selectivity.

Authors:  Min Chen; Minying Cai; David McPherson; Victor Hruby; Carroll M Harmon; Yingkui Yang
Journal:  Biochem Pharmacol       Date:  2008-09-30       Impact factor: 5.858

9.  Substitution of arginine with proline and proline derivatives in melanocyte-stimulating hormones leads to selectivity for human melanocortin 4 receptor.

Authors:  Hongchang Qu; Minying Cai; Alexander V Mayorov; Paolo Grieco; Morgan Zingsheim; Dev Trivedi; Victor J Hruby
Journal:  J Med Chem       Date:  2009-06-25       Impact factor: 7.446

10.  Discovery of Nanomolar Melanocortin-3 Receptor (MC3R)-Selective Small Molecule Pyrrolidine Bis-Cyclic Guanidine Agonist Compounds Via a High-Throughput "Unbiased" Screening Campaign.

Authors:  Skye R Doering; Katie Freeman; Ginamarie Debevec; Phaedra Geer; Radleigh G Santos; Travis M Lavoi; Marc A Giulianotti; Clemencia Pinilla; Jon R Appel; Richard A Houghten; Mark D Ericson; Carrie Haskell-Luevano
Journal:  J Med Chem       Date:  2021-04-22       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.